Hepbest Tablet

By Hepbest

Rx

30 Tablet in a Bottle

Composition icon

Composition

Tenofovir Alafenamide(25mg)

Manufacturer - Mylan Pharmaceuticals Pvt Ltd icon

Manufacturer - Mylan Pharmaceuticals Pvt Ltd

Mylan Pharmaceuticals Private Limited , Commercial Operations , Prestige Tech Park,Platina-3, 7th to 12th floor, Prestige Tech Park, Kadubesanahalli, Bangalore -560103

Expires on or after icon

Expires on or after

January, 2028

About Hepbest Tablet

Hepbest Tablet is a medication used to treat HIV infection and chronic hepatitis B virus (HBV) infection. It works by preventing the viruses from multiplying in human cells, stopping them from producing new viruses and clearing up the infection. It is essential to follow your doctor's advice on the dose and duration of taking Hepbest Tablet and not skip any doses, even if you start feeling better. Taking the tablet with food enhances its absorption into the body.

Common side effects of Hepbest Tablet include headache, diarrhea, nausea, joint pain, abdominal pain, and indigestion. While most of these side effects are not serious and may fade with time, it is advisable to consult your doctor if they persist. In rare cases, some individuals may experience skin reactions or liver damage, requiring close monitoring by the doctor during the initial stages of treatment.

Hepbest Tablet 30's, containing Tenofovir alafenamide, is specifically designed to treat chronic hepatitis B virus (HBV) infection in adults. It inhibits HBV replication by interfering with viral DNA synthesis, ultimately preventing the virus from producing new viruses and clearing the infection. Patients may experience side effects such as headaches, diarrhoea, nausea, vomiting, and rash, which usually do not require medical attention and may resolve over time.

It is important to inform your doctor about any skin problems, liver or kidney diseases before starting Hepbest Tablet 30's. Regular blood tests may be necessary during the course of treatment to monitor blood counts and liver function. Patients should avoid alcohol consumption as it can increase the risk of liver damage. Pregnant or breastfeeding individuals should seek their doctor's advice before using this medication.

HEPBEST 25MG TABLET, another form of Tenofovir alafenamide medication, is used to treat chronic hepatitis B infection in adolescents and adults. It is crucial to inform your doctor about any existing liver or kidney diseases, as well as any history of hepatitis C or D, HIV infection, or sugar intolerances. Precautions should be taken to avoid spreading the infection to others, especially through sexual contact.

This medication is not recommended for children under 12 years of age or those weighing less than 35 kgs. It is also advised to use caution in elderly patients aged 65 years and above. Common side effects of HEPBEST 25MG TABLET include headache, diarrhea, vomiting, nausea, dizziness, stomach pain, joint pain, rash, itching, and tiredness. Consult your doctor if any of these side effects worsen.


Disclaimer

The information provided on this website is to the best of our abilities to ensure it is accurate, reliable, and reviewed by a team of professionals. It should not be used to diagnose, prevent, or cure any health problem. The information presented here is not intended to create a doctor-patient relationship or replace a registered medical practitioner's advice, diagnosis, or treatment. The absence or provision of any information or warning regarding any medicine should not be assumed as an implied or explicit assurance of safety or efficacy. We highly recommend consulting your registered medical practitioner for all queries or doubts related to your medical condition. Do not ignore professional medical advice or delay seeking it based on the content encountered on our website. We intend to support, not replace, the doctor-patient relationship.

1642

Inclusive of all taxes

Content verified by

chevron-right

Dr. Gowri Kulkarni

MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)

Last update on 01-Oct-2024